logo-loader
viewGenprex, Inc.

Full interview: Genprex reveals positive preclinical data that shows synergies to fight lung cancers

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive its collaborators from The University of Texas MD Anderson Cancer Center presented data at the recent American Association of Cancer Research Tumor Immunology and Immunotherapy Meeting in Boston.

Varner talked through these important findings, highlighting how Genprex's positive preclinical data could help fight some of the most resistant metastatic lung cancers.

Quick facts: Genprex, Inc.

Price: 1.455 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $28.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex gets FDA Fast Track for its Oncoprex combination...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has been granted Fast Track Designation by the FDA for its Oncoprex immunogene therapy to treat lung cancer. Varner says the FDA validation is important, and gives the company more opportunities to meet with the...

4 days, 21 hours ago

2 min read